We found that all CRC patient samples presented for EGFR (% 66.66 COAD and 33.33% READ) and c-MET (58.33% COAD and 41.66% READ) expression profiling were positive for c-MET (Antibody: CAB005282) and EGFR (Antibody: HPA018530) signals (Figure 1D). This evidence concerns the gene EGFR and colorectal carcinoma.